Table 2—

Incidence of cardiovascular morbidity and mortality in the RENAAL study Asian population

Losartan (N = 117)
Placebo (N = 135)
Relative risk reduction95% CI
P value
EventsEvent rateEventsEvent rateLowerUpper
Primary composite end point4941.97454.80.350.070.550.020
 Components
  Doubling of serum creatinine3630.84835.60.26−0.010.520.167
  ESRD2218.83727.40.38−0.060.630.079
  Death1714.52115.60.10−0.710.520.753
Secondary composite end point*3529.94331.90.11−0.390.430.599
 Components
  Cardiovascular death97.7107.40.01−1.450.600.990
  Heart failure1512.81813.30.06−0.870.530.864
  Myocardial infarction54.3128.90.55−0.290.840.137
  Revascularization76.075.2−0.13−2.220.600.820
  Unstable angina76.032.2−1.61−9.100.320.164
  Stroke97.71410.40.29−0.640.690.423
  • *

    * Secondary composite end point of cardiovascular morbidity and mortality was a composite of myocardial infarction, stroke, hospitalization for heart failure, hospitalization for unstable angina, coronary and peripheral revascularization, and death due to cardiovascular causes. The relative risk reductions of losartan versus placebo were calculated with a Cox regression model, which was stratified by baseline proteinuria level. For the overall population, the model was also adjusted for region. (Positive relative risk reductions favor losartan.)